MARKETS
Markets

Guardant Health’s Shield Blood Test For Colorectal Cancer Screening To Be Covered In EviCore By Evernorth Clinical Guidelines Effective January 1, 2027, Per ACS Guidelines

Sep 14, 2026 · 04:08 PM ET· updated 54m ago

Second largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholdersMilestone marks rapid adoption by insurers

Share
Why It Matters

A big insurance company will now pay for Guardant's blood test for cancer screening. This shows doctors and insurance companies trust the test to help catch cancer early.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.